Business
Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds
Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds Canada NewsW...
About this update from Healwell Ai Inc. Class A
[{"type":"text","content":"\n\n\n\n Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Equity\n \n\n Insider\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Avant Technologies Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n April 29, 2025\n \n\n /CNW/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like\n \n Bill Gates\n \n have\n \n speculated about\n \n — the goal is to\n \n enhance the capabilities of healthcare professionals\n \n .\n \n Momentum in this space\n \n is being driven by recent initiatives from companies like\n \n Avant Technologies, Inc.\n \n (OTCQB: AVAI),\n \n Koninklijke Philips N.V.\n \n (NYSE: PHG),\n \n HEALWELL AI Inc.\n \n (TSX: AIDX) (OTCQX: HWAIF),\n \n RadNet, Inc.\n \n (NASDAQ: RDNT), and\n \n iCad, Inc.\n \n (NASDAQ: ICAD).\n \n\n\n\n\n\n\n\n\n The article continued:\n \n Barclays\n \n analysts forecast that the AI healthcare market will expand at a robust\n \n 30% CAGR through 2030\n \n , as investment from hospitals, insurers, and pharmaceutical giants continues to climb. A recent\n \n Deloitte\n \n\n study\n \n further notes that\n \n 71% of healthcare\n \n executives expect profitability to rise this year, in large part due to the growing integration of AI technologies into clinical operations.\n \n\n\n Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology\n \n\n\n\n Avant Technologies, Inc. (OTCQB: AVAI)\n \n , an emerging leader in\n \n AI-driven healthcare\n \n innovation, and its JV partner,\n \n Ainnova Tech, Inc., (Ainnova)\n \n , a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that\n \n The Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA)\...